BUZZ-Ceribell shares drop as losses exceed expectations, overshadowing better-than-expected revenue

November 4 - ** Medical device manufacturer Ceribell (CBLL.O) shares plummeted 15.8% in premarket trading to $23.8

** According to data compiled by London Stock Exchange Group (LSEG), the California-based company reported a third-quarter loss of $0.55 per share, while analysts had previously expected a loss of $0.51 per share

** Increased operating expenses—including investments in commercialization, R&D, equity incentives, and legal fees related to intellectual property—led to a wider loss this quarter

** However, the company raised the lower end of its annual revenue guidance from the previous forecast of $114 million–$117 million to $115 million–$117 million

** CBLL reported third-quarter revenue of $29.3 million, slightly above the analyst estimate of $29.16 million

** All eight brokerages covering the stock had a "buy" or higher rating; their median price target is $31—Reuters (LSEG) aggregated data

** As of the last trading day’s close, the stock has gained 28.9% year-to-date, compared to a 9.2% gain for the Nasdaq Composite Index over the same period .IXIC

(To assist non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translations may contain errors or may not provide the intended context, Reuters does not guarantee the accuracy of the translated texts and provides them for readers’ convenience only. Reuters accepts no responsibility for any damages or losses arising from the use of automated translation features.)